Acrivon Therapeutics is a clinical stage biopharmaceutical company developing oncology medicines by utilizing its proprietary proteomics-based patient responder identification platform. Co.'s Clinical Candidate ACR-368 is a selective small molecule inhibitor targeting CHK1 and CHK2. Using its Acrivon Predictive Precision Proteomics (AP3) platform, Co. has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature that can predict patient response to ACR-368 monotherapy. Co. also has two preclinical drug programs designed to take advantage of its AP3 platform and the ability to predict tumor sensitivity based on custom OncoSignature tests. The ACRV stock yearly return is shown above.
The yearly return on the ACRV stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ACRV annual return calculation with any dividends reinvested as applicable (on ex-dates).
|